Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K -: Investigating P1′ substituents

被引：22

作者：

Altmann, E ^{[1
]}

Green, J

Tintelnot-Blomley, M

机构：

[1] Novartis Pharma AG, Arthrit & Bone Metab Therapeut Area, CH-4002 Basel, Switzerland

[2] Novartis Pharma AG, Nervous Syst Therapeut Area, CH-4002 Basel, Switzerland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 12期

关键词：

D O I：

10.1016/S0960-894X(03)00344-5

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：1997 / 2001

页数：5

共 17 条

[1] Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors [J].

Altmann, E ;

Renaud, J ;

Green, J ;

Farley, D ;

Cutting, B ;

Jahnke, W .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2352-2354

[2] HUMAN CATHEPSIN O2, A NOVEL CYSTEINE PROTEASE HIGHLY EXPRESSED IN OSTEOCLASTOMAS AND OVARY MOLECULAR-CLONING, SEQUENCING AND TISSUE DISTRIBUTION [J].

BROMME, D ;

OKAMOTO, K .

BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1995, 376 (06) :379-384

[3] Cysteine proteases as therapeutic targets [J].

Brömme, D .

DRUG NEWS & PERSPECTIVES, 1999, 12 (02) :73-82

[4] Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts [J].

Drake, FH ;

Dodds, RA ;

James, IE ;

Connor, JR ;

Debouck, C ;

Richardson, S ;

LeeRykaczewski, E ;

Coleman, L ;

Rieman, D ;

Barthlow, R ;

Hastings, G ;

Gowen, M .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12511-12516

[5] Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L [J].

Falgueyret, JP ;

Oballa, RM ;

Okamoto, O ;

Wesolowski, G ;

Aubin, Y ;

Rydzewski, RM ;

Prasit, P ;

Riendeau, D ;

Rodan, SB ;

Percival, MD .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (01) :94-104

[6] The collagenolytic activity of cathepsin K is unique among mammalian proteinases [J].

Garnero, P ;

Borel, O ;

Byrjalsen, I ;

Ferreras, M ;

Drake, FH ;

McQueney, MS ;

Foged, NT ;

Delmas, PD ;

Delaissé, JM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (48) :32347-32352

[7] Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis [J].

Hou, WS ;

Brömme, D ;

Zhao, YM ;

Mehler, E ;

Dushey, C ;

Weinstein, H ;

Miranda, CS ;

Fraga, C ;

Greig, F ;

Carey, J ;

Rimoin, DL ;

Desnick, RJ ;

Gelb, BD .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (05) :731-738

[8] Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis [J].

Huang, L ;

Lee, A ;

Ellman, JA .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (03) :676-684

[9] MOLECULAR-CLONING OF HUMAN CDNA FOR CATHEPSIN-K - NOVEL CYSTEINE PROTEINASE PREDOMINANTLY EXPRESSED IN BONE [J].

INAOKA, T ;

BILBE, G ;

ISHIBASHI, O ;

TEZUKA, K ;

KUMEGAWA, M ;

KOKUBO, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (01) :89-96

[10] Protease inhibitors: Current status and future prospects [J].

Leung, D ;

Abbenante, G ;

Fairlie, DP .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (03) :305-341

← 1 2 →